Allozyne Licenses Scripps Chemistry

Xconomy Seattle — 

Allozyne, the Seattle-based developer of modified protein drugs, said today it has obtained a license to “click chemistry” technology from the lab of Nobel Laureate K. Barry Sharpless at The Scripps Research Institute in San Diego. Allozyne’s lead drug candidate uses the chemical binding technique to attach a polymer to a genetically engineered protein for multiple sclerosis. Allozyne has the exclusive license to use the chemistry for certain therapeutic uses, and a non-exclusive license for diagnostic uses. Financial terms weren’t disclosed.